Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy
about
Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding SiteImmunogenicity and Protective Efficacy of Brugia malayi Heavy Chain Myosin as Homologous DNA, Protein and Heterologous DNA/Protein Prime Boost Vaccine in Rodent ModelA Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing AntibodiesStructural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based ImmunogensStructure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing EpitopeA gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen RecognitionHepatitis C Virus E2 Envelope Glycoprotein Core StructureProgress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitopeComparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopesA recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy.HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodiesInduction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccinesStructure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.A novel retinoic acid, catechin hydrate and mustard oil-based emulsion for enhanced cytokine and antibody responses against multiple strains of HIV-1 following mucosal and systemic vaccinations.Multimeric scaffolds displaying the HIV-1 envelope MPER induce MPER-specific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNAStructure-based vaccine design in HIV: blind men and the elephant?Chimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responses.Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides.Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine designEngineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells.In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external regionThe membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine designRational design of membrane proximal external region lipopeptides containing chemical modifications for HIV-1 vaccination.Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteersNeutralizing antibodies to HIV-1 induced by immunization.Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccinationThe broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5.Electroporation-based DNA immunisation: translation to the clinic.An HIV/AIDS Prophylactic vaccine is possible.An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter genePolyvalent AIDS vaccines.
P2860
Q27319450-0FE06EF7-0CA0-4DC0-B94A-39B1B1689426Q27345320-213E5B85-363F-4B5E-B890-5C1E9563ABC5Q27655865-F0CFC44B-A72C-4170-8495-2919298AE4C4Q27658173-79D7D80F-143C-44D5-BA35-ABFC7EC8513BQ27675260-02B25626-EEE4-4961-9A87-DEEA5DE57CCCQ27676864-3186EBCA-7FF3-49FB-918D-B4E05E861FE5Q27680704-C03782EC-7663-48F2-8D7D-F6783ED03D65Q30379200-08224EED-9D49-44F2-B5ED-B4112B07B93DQ30843874-C46542C0-82AD-4B2A-803A-E06C9A4D21A5Q33417195-61136D2A-74E8-4AE1-AB47-F987F69C41DEQ33648910-2C864BC0-1EC4-478D-B4EB-CA1D4D3701E1Q33786140-F00AB6EC-AD46-4BD5-8C76-D1F5ADB3023FQ33869882-DA525112-90D4-481A-90F3-88D29D9D6712Q33916676-D7BCBCF9-9DAC-4176-85DF-EBF0EF7CD797Q34128200-8F81AC18-2F84-433F-9CFD-C6793C2D3B9DQ34204047-BD6E83CD-7C9E-4D7E-B9C9-F13203DEE195Q34262165-9B967F7D-0889-4F66-BD6B-F90A554E2DB1Q34396912-FAC6A950-F85E-44F5-BE89-F2E61E1A4072Q34551010-995E7450-F1D4-40ED-91EA-F79FFD6AB43CQ34663480-6B00A1C3-93F1-4FF1-BB0C-54761E2B5051Q34712503-DE10C072-F65A-4889-ADEC-F6417D59DA16Q34987048-60807B51-3CC2-49AA-B96A-BBB05E68035BQ34988326-F4D74B4E-2F4F-4F4B-8003-931C87126B5DQ35034311-C02686EB-C5D1-4B19-AC27-3B704F3BB260Q35196671-543CA59A-C761-43A9-83DF-D87A8BC3C549Q35666057-0B0E73F6-AE33-42BC-A7CF-DB49A1BBD3A0Q35745815-20DDDA18-D4E2-403C-A9BE-AC9BE0486911Q35947769-2CAE5F74-8B5D-4B90-8C7A-0CE3C7FD192BQ36303368-38E7E2FC-C2CB-46BD-B6DD-918E213FD78AQ36372534-09C07178-0B94-4EE1-89D2-98A23FBF8744Q36497712-9AC6A97A-1189-4FED-909D-CE0632E0E6F0Q36504833-ABFD5333-1006-4B3E-AB91-913256D65CC5Q36528901-39C5FBCA-0D92-4630-9B2D-69D9B3C6E675Q36603515-182F235C-36B7-40B4-9336-19C88565A629Q36804634-D5D4A777-54B5-4B84-9AB1-5EC211BB7615Q36898696-42387F86-3B1C-49D8-8005-1AB8A3873B57Q36981658-8E29E054-EA1B-4AA6-8714-2972DD45F9C2Q37037808-0E304603-4183-4E61-80A4-D17BB7D1A81DQ37064315-6642AC17-44D4-46D5-B88A-88B6A29F7F6AQ37094429-70A92E55-C664-44CD-9DF3-980AEA84AF96
P2860
Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Antigenic and immunogenic stud ...... in boost immunization strategy
@ast
Antigenic and immunogenic stud ...... in boost immunization strategy
@en
type
label
Antigenic and immunogenic stud ...... in boost immunization strategy
@ast
Antigenic and immunogenic stud ...... in boost immunization strategy
@en
prefLabel
Antigenic and immunogenic stud ...... in boost immunization strategy
@ast
Antigenic and immunogenic stud ...... in boost immunization strategy
@en
P2093
P2860
P356
P1433
P1476
Antigenic and immunogenic stud ...... in boost immunization strategy
@en
P2093
Dennis R Burton
Mansun Law
Rosa M F Cardoso
P2860
P304
P356
10.1128/JVI.02536-06
P407
P577
2007-01-31T00:00:00Z